WO2008015339A3 - Composition de facteur vii recombinant - Google Patents

Composition de facteur vii recombinant Download PDF

Info

Publication number
WO2008015339A3
WO2008015339A3 PCT/FR2007/001324 FR2007001324W WO2008015339A3 WO 2008015339 A3 WO2008015339 A3 WO 2008015339A3 FR 2007001324 W FR2007001324 W FR 2007001324W WO 2008015339 A3 WO2008015339 A3 WO 2008015339A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
factor vii
recombinant factor
vii composition
glycan
Prior art date
Application number
PCT/FR2007/001324
Other languages
English (en)
Other versions
WO2008015339A2 (fr
Inventor
Abdessatar Sami Chtourou
Emmanuel Nony
Nicolas Bihoreau
Original Assignee
Lfb Biotechnologies
Abdessatar Sami Chtourou
Emmanuel Nony
Nicolas Bihoreau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008015339(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2658800A priority Critical patent/CA2658800C/fr
Priority to AU2007280330A priority patent/AU2007280330B2/en
Priority to EP07823378A priority patent/EP2049150A2/fr
Priority to US12/374,269 priority patent/US20090239788A1/en
Priority to KR1020097001954A priority patent/KR101233630B1/ko
Application filed by Lfb Biotechnologies, Abdessatar Sami Chtourou, Emmanuel Nony, Nicolas Bihoreau filed Critical Lfb Biotechnologies
Priority to BRPI0715420-8A priority patent/BRPI0715420A2/pt
Priority to JP2009522304A priority patent/JP5653619B2/ja
Publication of WO2008015339A2 publication Critical patent/WO2008015339A2/fr
Publication of WO2008015339A3 publication Critical patent/WO2008015339A3/fr
Priority to IL196379A priority patent/IL196379A/en
Priority to US13/705,948 priority patent/US20130189244A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition de facteur VII recombinant ou transgénique, chaque molécule de facteur VII de la composition comportant des formes glycanniques liées aux sites de N-glycosylation, dans laquelle parmi toutes les molécules de facteur VII de ladite composition, des formes glycanniques biantennées, bisialylées et non fucosylées sont majoritaires. L'invention concerne également une telle composition pour son utilisation comme médicament, et, également, un procédé permettant de préparer entre autres ladite composition.
PCT/FR2007/001324 2006-08-01 2007-07-31 Composition de facteur vii recombinant WO2008015339A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2009522304A JP5653619B2 (ja) 2006-08-01 2007-07-31 遺伝子組み換えあるいは形質転換ｆｖｉｉ組成物およびその組成物を有効成分とする医薬
AU2007280330A AU2007280330B2 (en) 2006-08-01 2007-07-31 Recombinant Factor VII composition
EP07823378A EP2049150A2 (fr) 2006-08-01 2007-07-31 Composition de facteur vii recombinant
US12/374,269 US20090239788A1 (en) 2006-08-01 2007-07-31 Recombinant or transgenic factor vii compound having a majority of glycan, biantennary, bisialylated and non-fucosylated forms
KR1020097001954A KR101233630B1 (ko) 2006-08-01 2007-07-31 바이안테너리 비아시알릴화 및 비푸코실화된 형태의 다수의글리칸을 가지는 재조합 또는 형질전환 인자 ⅶ 화합물
CA2658800A CA2658800C (fr) 2006-08-01 2007-07-31 Composition de facteur vii recombinant ou transgenique comportant une majorite de formes glycanniques, biantennees, bisialylees et non fucosylees
BRPI0715420-8A BRPI0715420A2 (pt) 2006-08-01 2007-07-31 fator recombinante ou transgÊnico vii contendo uma maior parte de formas de glicano, formas biantenÁrias, bissialiladas e nço fucosiladas
IL196379A IL196379A (en) 2006-08-01 2009-01-07 Process for Preparing a Recombinant or Transgenic Factor Factor Composition with Most Glycan, Biantenary, Bisyaltic and Non-Focosylated Forms
US13/705,948 US20130189244A1 (en) 2006-08-01 2012-12-05 Recombinant or transgenic factor vii compound having a majority of glycan, biantennary, bisialylated and non-fucosylated forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607016A FR2904558B1 (fr) 2006-08-01 2006-08-01 "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR0607016 2006-08-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/705,948 Division US20130189244A1 (en) 2006-08-01 2012-12-05 Recombinant or transgenic factor vii compound having a majority of glycan, biantennary, bisialylated and non-fucosylated forms

Publications (2)

Publication Number Publication Date
WO2008015339A2 WO2008015339A2 (fr) 2008-02-07
WO2008015339A3 true WO2008015339A3 (fr) 2008-04-17

Family

ID=37903443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001324 WO2008015339A2 (fr) 2006-08-01 2007-07-31 Composition de facteur vii recombinant

Country Status (13)

Country Link
US (2) US20090239788A1 (fr)
EP (1) EP2049150A2 (fr)
JP (2) JP5653619B2 (fr)
KR (1) KR101233630B1 (fr)
CN (2) CN103397011B (fr)
AR (2) AR062162A1 (fr)
AU (1) AU2007280330B2 (fr)
BR (1) BRPI0715420A2 (fr)
CA (2) CA2876621A1 (fr)
FR (1) FR2904558B1 (fr)
IL (1) IL196379A (fr)
TW (1) TWI391400B (fr)
WO (1) WO2008015339A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275432A1 (fr) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration des solutions du facteur VII pour enlever des virus
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
WO2009118460A1 (fr) * 2008-03-25 2009-10-01 Bioprotein Technologies Sa Lapins transgeniques producteurs de facteur vii humain
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
WO2013017555A1 (fr) 2011-08-01 2013-02-07 Lfb-Biotechnologies Compositions de facteur vii ayant une glycosylation spécifique pour une demi-vie régulée
EP2554161A1 (fr) 2011-08-02 2013-02-06 LFB Biotechnologies Composition pharmaceutique comprenant factor VII encapsulé dans des micelles
WO2013114164A1 (fr) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation
MX2015010427A (es) 2013-02-13 2016-03-17 Lab Francais Du Fractionnement Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
EP2956003A2 (fr) * 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Protéines à glycosylation modifiée et leurs procédés de production
WO2016089919A1 (fr) 2014-12-01 2016-06-09 Amgen Inc. Procédé de manipulation du taux de contenu de glycane d'une glycoprotéine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475354A2 (fr) * 1990-09-11 1992-03-18 BEHRINGWERKE Aktiengesellschaft Sialysation des glycoprotéines par technologie génétique
WO2001058935A2 (fr) * 2000-02-11 2001-08-16 Maxygen Aps MOLECULES DE TYPE FACTEUR VII OU VIIa
WO2005024006A2 (fr) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Polypeptides du facteur vii de coagulation
WO2006004675A2 (fr) * 2004-06-25 2006-01-12 Altor Bioscience Corporation Production d'un facteur tissulaire chez des plantes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229342A (en) * 1977-05-18 1980-10-21 Rhone-Poulenc Industries Process for extracting proteins from milk using silica and anion exchange resins
NL8204923A (nl) * 1982-12-21 1984-07-16 Stichting Nl I Zuivelonderzoek Werkwijze voor het bereiden van een precipitaat van caseine en wei-eiwit alsmede aldus bereid precipitaat.
DE122007000007I2 (de) * 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
US6984772B1 (en) * 1994-02-18 2006-01-10 Virginia Tech Intellectual Properties, Inc. Transgenic non-human mammals producing fibrinogen in their milk
FR2684999A1 (fr) * 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9408717D0 (en) * 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
IL130964A0 (en) * 1997-01-16 2001-01-28 Cytel Corp Practical in vitro sialylation of recombinant glycoproteins
US5880237A (en) * 1997-01-31 1999-03-09 Nalco Chemical Company Preparation and utility of water-soluble polymers having pendant derivatized amide, ester or ether functionalities as ceramics dispersants and binders
US6238894B1 (en) * 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
US6183803B1 (en) * 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US6903069B2 (en) * 2000-10-02 2005-06-07 Novo Nordisk Health Care A/S Factor VII glycoforms
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
AU2003240439B2 (en) * 2002-06-21 2009-05-21 Novo Nordisk Health Care Ag Pegylated factor VII glycoforms
FR2841747B1 (fr) * 2002-07-02 2004-08-20 Cie Laitiere Europeenne Isolat de proteines de lait et procede pour sa preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475354A2 (fr) * 1990-09-11 1992-03-18 BEHRINGWERKE Aktiengesellschaft Sialysation des glycoprotéines par technologie génétique
WO2001058935A2 (fr) * 2000-02-11 2001-08-16 Maxygen Aps MOLECULES DE TYPE FACTEUR VII OU VIIa
WO2005024006A2 (fr) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Polypeptides du facteur vii de coagulation
WO2006004675A2 (fr) * 2004-06-25 2006-01-12 Altor Bioscience Corporation Production d'un facteur tissulaire chez des plantes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BJOERN S ET AL: "HUMAN PLASMA AND RECOMBINANT FACTOR VII CHARACTERIZATION OF O-GLYCOSYLATIONS AT SERINE RESIDUES 52 AND 60 AND EFFECTS OF SITE-DIRECTED MUTAGENESIS OF SERINE 52 TO ALANINE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 266, no. 17, 1991, pages 11051 - 11057, XP001086550, ISSN: 0021-9258 *
BOLT G ET AL: "POSTTRANSLATIONAL N-GLYCOSYLATION TAKES PLACE DURING THE NORMAL PROCESSING OF HUMAN COAGULATION FACTOR VII", GLYCOBIOLOGY, IRL PRESS,, GB, vol. 15, no. 5, May 2005 (2005-05-01), pages 541 - 547, XP009061442, ISSN: 0959-6658 *
JURLANDER B ET AL: "RECOMBINANT ACTIVATED FACTOR VII (RFVIIA): CHARACTERIZATION, MANUFACTURING, ND CLINICAL DEVELOPMENT", SEMINARS IN THROMBOSIS AND HEMOSTASIS, STUTTGART, DE, vol. 27, no. 4, August 2001 (2001-08-01), pages 373 - 383, XP008005254, ISSN: 0094-6176 *
THIM L ET AL: "Amino acid sequence and posttranslational modifications of human factor VII-a from plasma and transfected baby hamster kidney cells", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 27, no. 20, 1988, pages 7785 - 7793, XP002203678, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2008015339A2 (fr) 2008-02-07
CA2658800C (fr) 2015-03-31
FR2904558B1 (fr) 2008-10-17
EP2049150A2 (fr) 2009-04-22
KR20090040892A (ko) 2009-04-27
AR062162A1 (es) 2008-10-22
CN101495133A (zh) 2009-07-29
CA2876621A1 (fr) 2008-02-07
TWI391400B (zh) 2013-04-01
AR103027A2 (es) 2017-04-12
US20090239788A1 (en) 2009-09-24
AU2007280330A1 (en) 2008-02-07
JP2015042678A (ja) 2015-03-05
JP5653619B2 (ja) 2015-01-14
KR101233630B1 (ko) 2013-02-18
CA2658800A1 (fr) 2008-02-07
TW200825102A (en) 2008-06-16
CN103397011B (zh) 2016-10-05
JP2009545575A (ja) 2009-12-24
CN103397011A (zh) 2013-11-20
US20130189244A1 (en) 2013-07-25
IL196379A0 (en) 2011-08-01
FR2904558A1 (fr) 2008-02-08
AU2007280330B2 (en) 2011-11-10
IL196379A (en) 2016-04-21
BRPI0715420A2 (pt) 2013-07-02

Similar Documents

Publication Publication Date Title
WO2008015339A3 (fr) Composition de facteur vii recombinant
WO2007138199A3 (fr) Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
WO2006066594A3 (fr) Variantes de l'alpha-amylase
WO2007093627A3 (fr) Composition biocide
WO2008038257A3 (fr) Nouveaux produits d'addition et compositions aptes à durcir les utilisant
WO2007146945A3 (fr) Composites d'aérogel et de mousse
AU2007313300A8 (en) Molecules with reduced half-lives, compositions and uses thereof
WO2007095506A8 (fr) Modification des oligosaccharides et marquage des proteines
WO2008020405A3 (fr) Composés d'azétidine
WO2008021156A3 (fr) Anticorps dirigés contre l'il-17a
WO2008082613A3 (fr) Conjugués polymère-fraction à activité facteur ix comprenant une liaison dégradable
EP2041180B8 (fr) Molécules se liant à l'ilt3 et leurs utilisations
IL195675A (en) Human binding molecules with the ability to kill Staphylococcus preparations containing them, their method of manufacture and use
WO2008133722A3 (fr) Anticorps et diagnostics
WO2011053786A3 (fr) Produit protéique structuré exempt de gluten
WO2008118476A3 (fr) Affichage de surface d'une cellule, criblage et production de protéines d'intérêt
WO2006110651A3 (fr) Ecrans reflechissants et leurs procedes de fabrication
WO2007101698A3 (fr) Molecules modifiees destinees a promouvoir l'hematopoiese
WO2010006173A3 (fr) Complexe minéral-acide aminé-polysaccharide
WO2008030600A3 (fr) Composition de résine de polyamide
ATE478742T1 (de) Befestigungselement für bauelemente des trockenbaus und verfahren zur herstellung eines solchen befestigungselements
WO2007008072A3 (fr) Composes de liaison de structures beta-croisees
WO2008078189A3 (fr) Compositions de facteur vii et viia
WO2009103813A3 (fr) Compositions fongicides contenant du 3'-bromo-2,3,4,6'-tétraméthoxy-2'-6-diméthylbenzophénone
WO2009149218A3 (fr) Nouvelles protéines et procédés de conception et d'utilisation de celles-ci

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780027968.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823378

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007280330

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 485/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2658800

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009522304

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097001954

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007280330

Country of ref document: AU

Date of ref document: 20070731

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007823378

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12374269

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0715420

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090128